Subscribe

Study Summaries

GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma

Adjuvant chemotherapy with gemcitabine plus docetaxel followed by doxorubicin does not show superior outcomes compared to observation for high-grade uterine leiomyosarcoma.

GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas

Doxorubicin remains the standard first-line treatment for most patients with advanced soft-tissue sarcoma, as gemcitabine and docetaxel did not demonstrate superiority in survival outcomes

LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma

The combination of doxorubicin and trabectedin significantly improves progression-free survival compared to doxorubicin alone for the first-line treatment of metastatic or unresectable leiomyosarcoma, with an acceptable safety profile despite increased toxicity.

GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol

CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol

NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

NRG-GY012

DESKTOP Trial - Secondary Debulking Surgery

Secondary debulking surgery in recurrent ovarian cancer

PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk

Vaginal Brachytherapy vs. Pelvic External Beam Radiotherapy in Endometrial Cancer (PORTEC-2)

RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer